James Krieg, MD
Family Medicine · Chester, ILNPI 1851402390
Payments from drug & device makers
Across 151 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$372
- AstraZeneca$319
- GSK$238
- Pfizer$214
- Dexcom, Inc.$181
- Boehringer Ingelheim$171
- plus $847 from 21 others
What the payments were for
- Food & beverage$2,342100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $372 |
| AstraZeneca | 22 | $319 |
| GSK | 20 | $238 |
| Pfizer | 12 | $214 |
| Dexcom, Inc. | 9 | $181 |
| Boehringer Ingelheim | 10 | $171 |
| Novo Nordisk | 7 | $126 |
| E.r. Squibb & Sons, L.L.C. | 7 | $111 |
| Sumitomo Pharma America, Inc. | 9 | $96 |
| Astellas Pharma US Inc | 4 | $65 |
| Johnson & Johnson | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Bayer | 3 | $44 |
| Merck | 2 | $39 |
| Amgen | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Lundbeck LLC | 1 | $25 |
| Novartis | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Si-bone, Inc. | 1 | $13 |
| Dermira, Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
How this compares
$2,342 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 183 | $141,100 |
| TrulicityDulaglutide | 77 | $96,667 |
| JardianceEmpagliflozin | 103 | $74,456 |
| JanuviaSitagliptin Phosphate | 122 | $73,788 |
| FarxigaDapagliflozin Propanediol | 79 | $58,003 |
| GemtesaVibegron | 69 | $42,600 |
| EntrestoSacubitril/Valsartan | 43 | $28,948 |
| XareltoRivaroxaban | 35 | $28,218 |
| OzempicSemaglutide | 20 | $25,748 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $21,254 |
| RexultiBrexpiprazole | 12 | $17,063 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $15,966 |
| TradjentaLinagliptin | 15 | $15,464 |
| ElmironPentosan Polysulfate Sodium | 26 | $12,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $214 | $153,996224 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $171 | $96,731130 claims |
| Lilly USA, LLCTrulicity | $372 | $96,66777 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $319 | $88,435141 claims |
| MerckJanuvia | $39 | $73,788122 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Incruse Ellipta | $238 | $52,643114 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $96 | $42,60069 claims |
| NovartisEntresto | $23 | $28,94843 claims |
| Johnson & JohnsonXarelto | $58 | $28,21835 claims |
| Novo NordiskOzempic | $126 | $25,74820 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $12 | $17,06312 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $6,39520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chester
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.